Skip to main content

Table 2 Threshold effect analyses of serum AOPP (per SD increment) on all-cause mortality and CVD mortality using two-piecewise regression models

From: Association between serum advanced oxidation protein products and mortality risk in maintenance hemodialysis patients

AOPP, µmol/L Case Incident rate (%) Unadjusted model Adjusted model*
HR (95% CI) P value HR (95% CI) P value
All-cause mortality
 < 87 332 29.5 0.97 (0.87,1.08) 0.561 0.94 (0.84,1.05) 0.295
 ≥ 87 160 36.3 1.25 (1.10,1.43)  < 0.001 1.24 (1.08,1.42) 0.002a
CVD mortality
 < 88 242 21.0 0.95 (0.84,1.08) 0.421 0.89 (0.78,1.01) 0.068
 ≥ 88 98 23.7 1.19 (1.00,1.42) 0.046 1.26 (1.05,1.52) 0.015
  1. *Adjusted for age, sex, BMI, smoking, dialysis vintage, hemoglobin, phosphate, iron supplement, use of phosphorus binder, study centers, CVD status, hypertension status and diabetes status at baseline
  2. aFor the primary outcome (all-cause mortality), since there are two times assessments, we used the Bonferroni method and accepted P < 0.025 as significant